12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dermacyn Wound regulatory update

Oculus said the British Standards Institution (BSI) and the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved CE Mark reclassification of its Dermacyn wound care product to a Class III...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >